{"id":3816,"date":"2017-06-26T05:43:13","date_gmt":"2017-06-26T05:43:13","guid":{"rendered":"http:\/\/blogs.sld.cu\/oserranob\/?p=3816"},"modified":"2017-06-26T13:32:25","modified_gmt":"2017-06-26T13:32:25","slug":"riesgo-de-cancer-para-portadoras-de-mutaciones-en-brca12","status":"publish","type":"post","link":"https:\/\/blogs.sld.cu\/oserranob\/2017\/06\/26\/riesgo-de-cancer-para-portadoras-de-mutaciones-en-brca12\/","title":{"rendered":"Riesgo de c\u00e1ncer para portadoras de mutaciones en BRCA1\/2"},"content":{"rendered":"<p style=\"text-align: justify\"><a href=\"https:\/\/blogs.sld.cu\/oserranob\/files\/2017\/06\/2017-06-24-BRCA.jpg\"><img loading=\"lazy\" class=\"alignleft wp-image-3843 size-full\" style=\"border-width: 1px;margin: 5px\" title=\"(c) Kuchenbaecker KB, et al. JAMA 2017\" src=\"https:\/\/blogs.sld.cu\/oserranob\/files\/2017\/06\/2017-06-24-BRCA.jpg\" alt=\"2017 06 24 BRCA\" width=\"85\" height=\"71\" \/><\/a>Nuevos estimados de riesgo de <a title=\"Informaci\u00f3n sobre la enfermedad en OMIM\" href=\"http:\/\/omim.org\/entry\/114480\" target=\"_blank\">c\u00e1ncer de mama<\/a>, <a title=\"Informaci\u00f3n sobre la enfermedad en OMIM\" href=\"http:\/\/omim.org\/entry\/167000\" target=\"_blank\">ovario<\/a> o c\u00e1ncer contralateral en mujeres portadoras de mutaciones en los genes <a title=\"Informaci\u00f3n sobre el gen en Gene\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/gene\/672\" target=\"_blank\">BRCA1<\/a> y <a title=\"Informaci\u00f3n sobre el gen en Gene\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/gene\/675\" target=\"_blank\">BRCA2<\/a> son calculados para la edad, los antecedentes positivos y la localizaci\u00f3n de la mutaci\u00f3n. A los 80 a\u00f1os de edad estos tumores malignos\u00a0 aparecen en m\u00e1s del 60 % de las portadoras. Los resultados son presentados en Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, <em>et al<\/em>. <a title=\"Texto completo en ingl\u00e9s\" href=\"http:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2632503\" target=\"_blank\">Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers<\/a>. JAMA. 2017;317(23):2402-2416.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nuevos estimados de riesgo de c\u00e1ncer de mama, ovario o c\u00e1ncer contralateral en mujeres portadoras de mutaciones en los genes BRCA1 y BRCA2 son calculados para la edad, los antecedentes positivos y la localizaci\u00f3n de la mutaci\u00f3n. A los 80 a\u00f1os de edad estos tumores malignos\u00a0 aparecen en m\u00e1s del 60 % de las portadoras. [&hellip;]<\/p>\n","protected":false},"author":125,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[11,15,29],"tags":[],"_links":{"self":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/3816"}],"collection":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/users\/125"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/comments?post=3816"}],"version-history":[{"count":4,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/3816\/revisions"}],"predecessor-version":[{"id":3855,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/3816\/revisions\/3855"}],"wp:attachment":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/media?parent=3816"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/categories?post=3816"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/tags?post=3816"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}